115activity parameters at a certain time of management, to playing an active role in the
diagnosis, assessment of disease activity, monitoring of comorbidities, adherence to
therapy, and patient self-management. PROMs also evolved from the generic phase
into a disease-specifi c era. Embedding PROMs in the decision-making process has
facilitated fi lling the gap between the standard clinical practice and the growing role
of health economics.
References
- Arthritis Alliance of Canada. The impact of arthritis in Canada: today and over the next 30
years. 2011. http://www.arthritisnetwork.ca/downloads/20111022_Impact_of_arthritis.pdf.
Accessed 20 Jul 2012. - El Miedany Y. Comorbidity index in rheumatoid arthritis. Time to think. Clin Rheumatol.
2015;34:1995–2000. - Palmer D, El Miedany Y. Shared decision making for patients living with infl ammatory
arthritis. Br J Nurs. 2016;25(1):2–6. - Boers M, Tugwell P, Felson DT, van Riel PL, Kirwan JR, Edmonds JP, et al. World Health
Organization and International League of Associations for Rheumatology core endpoints for
symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol.
1994;21 Suppl 41:86–9. - Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American
College of Rheumatology preliminary core set of disease activity measures for rheumatoid
arthritis clinical trials. The committee on outcome measures in rheumatoid arthritis clinical
trials. Arthritis Rheum. 1993;36:729–40. - Gossec L, Dougados M, Rincheval N, Balanescu A, Boumpas DT, Canadelo S, et al.
Elaboration of the preliminary rheumatoid arthritis impact of disease (RAID) score: a
EULAR initiative. Ann Rheum Dis. 2009;68(11):1680–5. - Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, et al. Reporting
disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collab-
orative recommendations. Ann Rheum Dis. 2008;67:1360–4. - Pincus T, Wolfe F. Patient questionnaires for clinical research and improved standard patient
care: is it better to have 80% of the information in 100% of patients or 100% of the informa-
tion in 5% of patients? J Rheumatol. 2005;32:575–7. - El Miedany Y, El Gaafary M, Ahmed I, Youssef S, Nasr A. US guided treat-to-target approach
in early RA: implications for uncoupling of disease activity and structural joint damage. Curr
Rheumatol Rev. 2015;11:18–27. - Saag KG, Yazdany J, Alexander C, Caplan L, Coblyn J, Desai SP, American College of
Rheumatology Quality Measurement White Paper Development Workgroup, et al. Defi ning
quality of care in rheumatology: the American College of Rheumatology white paper on
quality measurement. Arthritis Care Res (Hoboken). 2011;63(1):2–9. - Cadena J, Vinaccia S, Pérez A, Rico MI, Hinojosa R, Anaya JM. The impact of disease activ-
ity on the quality of life, mental health status and family dysfunction in Colombian patients
with rheumatoid arthritis. J Clin Rheumatol. 2003;9(3):142–50. - Smedstad LM, Vaglum P, Kvien TK, Moum T. The relationship between self-reported pain
and sociodemographic variables, anxiety and depressive symptoms in rheumatoid arthritis.
J Rheumatol. 1995;22(3):514–20. - Birrell FN, Hassell AB, Jones PW, Dawes PT. How does the short form 36 health question-
naire (SF-36) in rheumatoid arthritis relate to RA outcome measures and SF-36 population
values? A cross sectional study. Clin Rheumatol. 2000;19(3):195–9.
4 PROMs for Rheumatoid Arthritis